- Home
- HCA vs REGN Comparison
HCA vs REGN Comparison
Compare HCA & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCA
- REGN
- Stock Information
- Founded
- HCA 1968
- REGN 1988
- Country
- HCA United States
- REGN United States
- Employees
- HCA N/A
- REGN N/A
- Industry
- HCA Hospital/Nursing Management
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- HCA Health Care
- REGN Health Care
- Exchange
- HCA Nasdaq
- REGN Nasdaq
- Market Cap
- HCA 90.9B
- REGN 59.5B
- IPO Year
- HCA N/A
- REGN 1991
- Fundamental
- Price
- HCA $400.85
- REGN $598.71
- Analyst Decision
- HCA Buy
- REGN Buy
- Analyst Count
- HCA 17
- REGN 23
- Target Price
- HCA $408.79
- REGN $794.83
- AVG Volume (30 Days)
- HCA 1.1M
- REGN 940.7K
- Earning Date
- HCA 10-24-2025
- REGN 10-30-2025
- Dividend Yield
- HCA 0.72%
- REGN 0.59%
- EPS Growth
- HCA 11.48
- REGN 5.03
- EPS
- HCA 23.73
- REGN 39.67
- Revenue
- HCA $72,698,000,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- HCA $7.33
- REGN N/A
- Revenue Next Year
- HCA $4.37
- REGN $4.86
- P/E Ratio
- HCA $16.90
- REGN $15.09
- Revenue Growth
- HCA 6.37
- REGN 5.38
- 52 Week Low
- HCA $289.98
- REGN $476.49
- 52 Week High
- HCA $420.98
- REGN $1,165.85
- Technical
- Relative Strength Index (RSI)
- HCA 51.73
- REGN 56.40
- Support Level
- HCA $385.59
- REGN $552.98
- Resistance Level
- HCA $406.61
- REGN $570.76
- Average True Range (ATR)
- HCA 11.42
- REGN 11.23
- MACD
- HCA -2.51
- REGN -31.73
- Stochastic Oscillator
- HCA 43.12
- REGN 99.79
About HCA HCA Healthcare Inc.
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the United States. As of December 2024, the firm owned and operated 190 hospitals, 124 freestanding outpatient surgery centers, and a broad network of physician offices, urgent-care clinics, and freestanding emergency rooms across 20 states and a small foothold in England.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).